Critical Path Institute President/CEO Receives Award of Excellence Raymond L. Woosley, MD, PhD, President/CEO of Tucson-based Critical Path Institute (CPI), was recently presented with the prestigi
Critical Path Institute Announces New Board Members Bonnie A. Allin and Louis Breton Critical Path Institute (C-Path) today announced the appointments of Bonnie A. Allin and Louis Breton to its Board of Directors.
C-Path, CPP Share Manuscript That Redefines Parkinson’s Disease C-Path and its Critical Path for Parkinson’s Consortium are pleased to share a new manuscript that redefines Parkinson’s...
eCOA Consortium Announces New Article for Applied Clinical Trials C-Path’s eCOA Consortium is pleased to announce that “Implementing Numeric Rating and Visual Analog Scales in an eCOA Soluti
eCOA Consortium Announces New Article for Applied Clinical Trials C-Path’s eCOA Consortium is pleased to announce that “Survey Investigates Backup Solution Adoption for ePRO Systems” has bee
eCOA Consortium Announces New Article for Applied Clinical Trials C-Path’s eCOA Consortium is pleased to announce that “Evaluating the Use of Backup Solutions for ePRO Systems” has been publ
eCOA Consortium Announces Next Article in a Series for Applied Clinical Trials C-Path’s eCOA Consortium is pleased to announce that “Progressing BYOD Adoption” has been published in Applied Clinical Tria
eCOA Consortium Announces Next Article in a Series for Applied Clinical Trials C-Path’s eCOA Consortium is pleased to announce that “Administering Complex Cognitive Tests Remotely in The Cognitively-Impair
C-Path Awarded FDA Drug Development Tool Research Grant to Develop a Qualification Plan for the Symptoms of Major Depressive Disorder Momentary Assessment (SMDDMA) C-Path’s Patient-Reported Outcome (PRO) Consortium announced that it has been awarded a U.S. Food and Drug Administration (FDA)
C-Path Awarded FDA Drug Development Tool Research Grant to Develop a Qualification Plan for the PROMIS® Short Form v2.1—Physical Function-Multiple Sclerosis 15a (PROMIS PFMS—15a) C-Path’s Patient-Reported Outcome (PRO) Consortium announced today it has been awarded a U.S. Food and Drug Administratio